您好！歡迎訪問上海起發(fā)實(shí)驗(yàn)試劑有限公司網(wǎng)站！
全國服務(wù)咨詢熱線:
15921799099
15921799099
荷蘭ipatherapeutics生物公司是ImmunoPrecise Antibodies Ltd.（NASDAQ: IPA）旗下的重要品牌，是一家在生物治療領(lǐng)域具有影響力的合同研究組織。公司成立于1989年，總部位于美國法戈，并在北美和歐洲設(shè)有多個(gè)分支機(jī)構(gòu)，員工規(guī)模在51至200人之間。該公司專注于抗體發(fā)現(xiàn)與開發(fā)服務(wù)，致力于通過融合生物技術(shù)和人工智能技術(shù)推動(dòng)生物治療創(chuàng)新。
ipatherapeutics的核心技術(shù)平臺(tái)包括其獨(dú)特的B細(xì)胞選擇®兔單克隆抗體技術(shù)、轉(zhuǎn)基因動(dòng)物模型以及多通道膜蛋白靶向抗體平臺(tái)。兔免疫系統(tǒng)的優(yōu)勢在于能產(chǎn)生高特異性和高親和力抗體，結(jié)合公司功能優(yōu)先的B細(xì)胞選擇工作流程，可在早期識(shí)別出優(yōu)秀的診斷抗體面板。其轉(zhuǎn)基因動(dòng)物模型能夠針對(duì)小于3 kDa的小分子和具有復(fù)雜二級(jí)結(jié)構(gòu)的蛋白質(zhì)生成大量序列多樣、生物學(xué)相關(guān)的候選抗體。在多通道膜蛋白靶向抗體方面，公司通過BLI平臺(tái)進(jìn)行特異性測試，結(jié)合抗體面板的親和力排名或表位映射和分箱，實(shí)現(xiàn)分子質(zhì)量優(yōu)化。
公司近年來積極整合人工智能技術(shù)，特別是其LENSai™計(jì)算軟件平臺(tái)和HYFT技術(shù)，通過多組學(xué)建模和復(fù)雜的人工智能系統(tǒng)支持抗體發(fā)現(xiàn)過程。2023年，公司通過收購BioStrand獲得了一套基于云的革命性解決方案，能夠加速多組學(xué)研究數(shù)據(jù)分析。此外，公司的OmniChicken®發(fā)現(xiàn)平臺(tái)是行業(yè)內(nèi)成功改造的鳥類平臺(tái)，具有能夠產(chǎn)生人類序列抗體庫的免疫系統(tǒng)。
ipatherapeutics提供抗體開發(fā)服務(wù)，涵蓋從定制單克隆和多克隆抗體開發(fā)、抗體工程與優(yōu)化到抗體生產(chǎn)和純化的完整流程。公司服務(wù)對(duì)象包括制藥公司、生物技術(shù)企業(yè)、研究機(jī)構(gòu)和學(xué)術(shù)界客戶。其產(chǎn)品線涵蓋多種研究用抗體，包括針對(duì)各種疾病靶點(diǎn)的單克隆抗體，例如貨號(hào)MQ13.101的鼠標(biāo)抗瓜氨酸纖維蛋白原抗體和貨號(hào)MQR2.201的人抗凋亡 cleavage product of human U1-70K抗體等。
公司將自身定位為“生物治療智能的中心"，通過結(jié)合專業(yè)知識(shí)和技術(shù)，為制藥合作伙伴提供高度專業(yè)化的全連續(xù)治療性抗體發(fā)現(xiàn)、開發(fā)和對(duì)外許可服務(wù)。公司的使命是為制藥客戶提供智能和技術(shù)來治療疾病，目標(biāo)是提高生物治療的特異性。
關(guān)鍵詞：ipatherapeutics，ipatherapeutics上海代理，ipatherapeutics中國代理，ipatherapeutics北京代理，ipatherapeutics江蘇代理， ipatherapeutics廣東代理,N002-100ML, N001-0.5mg, N001-0.1mg, R001-100ML, L101-0.025mg immunoprecise u-proteinexpress、ipatherapeutics、免疫精確抗體、IPA生物治療、B細(xì)胞選擇兔單克隆抗體、人工智能抗體發(fā)現(xiàn)、LENSai平臺(tái)、OmniChicken技術(shù)、轉(zhuǎn)基因動(dòng)物模型、多通道膜蛋白靶向、抗體發(fā)現(xiàn)服務(wù)、生物治療智能、定制抗體開發(fā)、HYFT技術(shù)、治療性抗體、生物制藥研發(fā)、GPCR抗體、結(jié)構(gòu)生物學(xué)、抗體人源化、生物標(biāo)記物發(fā)現(xiàn)、臨床前開發(fā)。
特別告知：為保證產(chǎn)品質(zhì)量與良好性能，所以在購買相應(yīng)產(chǎn)品的同時(shí)我司會(huì)收取一定量的運(yùn)輸費(fèi)用?。?！本次報(bào)價(jià)有效時(shí)間為2025年12月19日---2026年12月20日。
（*此為部分產(chǎn)品價(jià)格,完整價(jià)格請(qǐng)下載文件)
貨號(hào) | 品名 | 規(guī)格 | 價(jià)格 | 品牌 |
N001-0.1 mg | WNT Surrogate-Fc Fusion Protein | 100µg | 17641.8 | ipatherapeutics |
N001-0.5 mg | WNT Surrogate-Fc Fusion Protein | 500µg | 70270.2 | ipatherapeutics |
N001-1.0 mg | WNT Surrogate-Fc Fusion Protein | 1mg | 105454.8 | ipatherapeutics |
N002-100 ml | Noggin-Fc Fusion Protein Conditioned Medium | 100ml | 24690.6 | ipatherapeutics |
N002-200 ml | Noggin-Fc Fusion Protein Conditioned Medium | 200ml | 44569.8 | ipatherapeutics |
N002-500 ml | Noggin-Fc Fusion Protein Conditioned Medium | 500ml | 64548 | ipatherapeutics |
O001 | OIT1, Murine | 100ug | 9603 | ipatherapeutics |
P001 | Platelet Derived Growth Factor Βeta, Human | 100ug | 9999 | ipatherapeutics |
P002 | PDGF-R Beta-(His)C, ECD, Human, Recombinant | 100ug | 10711.8 | ipatherapeutics |
R001-100 ml | Rspo3-Fc Fusion Protein Conditioned Medium | 100ml | 24690.6 | ipatherapeutics |
R001-200 ml | Rspo3-Fc Fusion Protein Conditioned Medium | 200ml | 44569.8 | ipatherapeutics |
R001-500 ml | Rspo3-Fc Fusion Protein Conditioned Medium | 500ml | 64548 | ipatherapeutics |
R002-0.1 mg | mRSPO1-Fc | 0.1mg | 9801 | ipatherapeutics |
R002-0.5 mg | mRSPO1-Fc | 0.5mg | 38966.4 | ipatherapeutics |
R002-1.0 mg | mRSPO1-Fc | 1.0mg | 58429.8 | ipatherapeutics |
R005-0.1 mg | mRSPO1-his | 0.1mg | 9801 | ipatherapeutics |
R005-0.5 mg | mRSPO1-his | 0.5mg | 38966.4 | ipatherapeutics |
R005-1.0 mg | mRSPO1-his | 1.0mg | 58429.8 | ipatherapeutics |
R006-0.1 mg | hRSPO1-Fc | 0.1mg | 9801 | ipatherapeutics |
R006-0.5 mg | hRSPO1-Fc | 0.5mg | 38966.4 | ipatherapeutics |
R006-1.0 mg | hRSPO1-Fc | 1.0mg | 58429.8 | ipatherapeutics |
R006-2.0 mg | hRSPO1-Fc | 2.0mg | 88723.8 | ipatherapeutics |
R007-0.1 mg | hRSPO1-his | 0.1mg | 9801 | ipatherapeutics |
R007-0.5 mg | hRSPO1-his | 0.5mg | 38966.4 | ipatherapeutics |
R007-1.0 mg | hRSPO1-his | 1.0mg | 58429.8 | ipatherapeutics |
R009-10 ml | enhanced Rspo3-Fc Fusion Protein Conditioned Medium | 10ml | 24472.8 | ipatherapeutics |
R009-50 ml | enhanced Rspo3-Fc Fusion Protein Conditioned Medium | 50ml | 97891.2 | ipatherapeutics |
R010-0.1 mg | enhanced Rspo3-Fc Fusion Protein | 0.1mg | 24472.8 | ipatherapeutics |
R010-0.5 mg | enhanced Rspo3-Fc Fusion Protein | 0.5mg | 97891.2 | ipatherapeutics |
S001 | Sp-D, Porcine | 100ug | 9603 | ipatherapeutics |
S002 | Sp-D, Human | 100ug | 9603 | ipatherapeutics |
S003A | Syndecan-1-(His)C, Human, Recombinant, higher glycosylation than S003B | 100µg | 10098 | ipatherapeutics |
S003B | Syndecan-1-(His)C, Human, Recombinant, lower glycosylation than S003A | 100µg | 10098 | ipatherapeutics |
T004 | Tev Protease | 1mg | 18255.6 | ipatherapeutics |
T005 | TFPI-Alpha-(His)C, Human, Recombinant | 100µg | 11226.6 | ipatherapeutics |
T006 | Thrombomodulin-(Tev-His)N, Human, Recombinant | 100µg | 11226.6 | ipatherapeutics |
U001 | Upar-(His)N, Human, Recombinant | 100ug | 10098 | ipatherapeutics |
V001 | vWF-A1 Domain, Human, Residues 1261-1468 | 100ug | 8375.4 | ipatherapeutics |
V002 | vWF-A1 Domain, Human, Residues 1261-1468, VWD Type 2B, Recombinant | 100ug | 8989.2 | ipatherapeutics |
V003 | vWF-A1 Domain, Human, Residues 1238-1481, Glycosylated | 100ug | 10711.8 | ipatherapeutics |
V004 | vWF-A3 Domain, Human, Residues 1683-1874, Recombinant | 100ug | 9603 | ipatherapeutics |
V005 | vWF-A3 Domain, Human, Residues 1683-1874, without Tag, Recombinant | 100ug | 10197 | ipatherapeutics |
V010 | VCAM1-(His)N, Transcript A, Human, Recombinant | 100ug | 11226.6 | ipatherapeutics |
V011 | vWF-A1-A2-A3-(his)C domain, Human, Residues 1261-1874, Recombinant | 100µg | 13068 | ipatherapeutics |
V012 | vWF-A1-A2-A3-R1597Q-(his)C domain, Human, Residues 1261-1874, Recombinant | 100µg | 13068 | ipatherapeutics |
PODI-0005 | mouse anti-barley LTP | 100ug | 8375.4 | ipatherapeutics |
PODI-0006 | mouse anti-human ACTH (POMC) | 100ug | 8375.4 | ipatherapeutics |
PODI-0007 | mouse anti-rabbit uteroglobuline | 100ug | 8375.4 | ipatherapeutics |
PODI-0008 | mouse anti-Trichinella spiralis | 100ug | 8375.4 | ipatherapeutics |
PODI-0009 | mouse anti-Leptospira interogans OMP (2D1D7) | 100ug | 8375.4 | ipatherapeutics |
PODI-0011 | mouse anti-Cowdria ruminantium OMP (1E5H8) | 100ug | 8375.4 | ipatherapeutics |
PODI-0012 | mouse anti-Cowdria ruminantium OMP (4F10B4) | 100ug | 8375.4 | ipatherapeutics |
PODI-0013 | mouse anti-human HSP60, specific for eukaryotic HSP60 | 100ug | 8375.4 | ipatherapeutics |
PODI-0014 | mouse anti-human HSP60, specific for eukaryotic and prokaryotic HSP60 | 100ug | 8375.4 | ipatherapeutics |
PODI-0015 | mouse anti-HSP70, cross reactive with E.coli DNAK | 100ug | 8375.4 | ipatherapeutics |
PODI-0016 | mouse anti-sheep IgE | 100ug | 8375.4 | ipatherapeutics |
PODI-0017 | mouse anti-rat gonocytes | 100ug | 8375.4 | ipatherapeutics |
PODI-0018 | mouse anti-chloroamphenicol | 100ug | 8375.4 | ipatherapeutics |
PODI-0019 | mouse anti-human PLK1 | 100ug | 8375.4 | ipatherapeutics |
PODI-0023 | mouse anti-human PBDK1 | 100ug | 8375.4 | ipatherapeutics |
PODI-0027 | mouse anti-human PBDK2 | 100ug | 8375.4 | ipatherapeutics |
PODI-0031 | mouse anti-human Mps1 | 100ug | 8375.4 | ipatherapeutics |
PODI-0034 | mouse anti-GFP | 100ug | 8375.4 | ipatherapeutics |
PODI-0035 | mouse anti-human MASP-2 | 100ug | 8375.4 | ipatherapeutics |
PODI-0037 | mouse anti-human FAM3D | 100ug | 8375.4 | ipatherapeutics |
PODI-0038 | mouse anti-human FAM3D, cross reacts with mouse Oit-1 | 100ug | 8375.4 | ipatherapeutics |
PODI-0039 | mouse anti-human MBL-2 | 100ug | 8375.4 | ipatherapeutics |
PODI-0040 | human Placental Alkaline Phosphatase (2B4H11) | 100ug | 8375.4 | ipatherapeutics |
PODI-0042 | human Placental Alkaline Phosphatase (23F4G3) | 100ug | 8375.4 | ipatherapeutics |
PODI-0043 | human Intestinal Alkaline Phosphatase (8A8E3) | 100ug | 8375.4 | ipatherapeutics |
PODI-0058 | mouse anti-rat CD40 | 100ug | 8375.4 | ipatherapeutics |
PODI-0059 | mouse anti-Ovalbumin | 100ug | 8375.4 | ipatherapeutics |
PODI-0061 | mouse anti-Neisseria meningitidis Omp85 (32F9) | 100ug | 8375.4 | ipatherapeutics |
PODI-0063 | mouse anti-Lactobacillus rhamnosus SpaC | 100ug | 8375.4 | ipatherapeutics |
PODI-0064 | mouse anti-Streptococcus pneumonia PspA | 100ug | 8375.4 | ipatherapeutics |
PODI-0065 | mouse anti-human PDGF | 100ug | 8375.4 | ipatherapeutics |
PODI-0068 | mouse anti-human CD36, cross reacts with dog | 100ug | 8375.4 | ipatherapeutics |
PODI-0069 | mouse anti-STREP-II tag | 100ug | 8375.4 | ipatherapeutics |
PODI-0070 | mouse anti-human Mart-1, IHC on melanoma tissue | 100ug | 8375.4 | ipatherapeutics |
PODI-0071 | mouse anti-human BCHE | 100ug | 8375.4 | ipatherapeutics |
PODI-0073 | mouse anti-human IGFBP-7 | 100ug | 8375.4 | ipatherapeutics |
PODI-0076 | mouse anti-Neisseria meningitidis Omp85 | 100ug | 8375.4 | ipatherapeutics |
PODI-0077 | mouse anti-N-terminal-His tag | 100ug | 8375.4 | ipatherapeutics |
PODI-0079 | human Intestinal Alkaline Phosphatase, detector antibody in ELISA with 8A8E3 | 100ug | 8375.4 | ipatherapeutics |
PODI-0080 | mouse anti-human Factor V | 100ug | 8375.4 | ipatherapeutics |
PODI-0081 | mouse anti-human PKM2 | 100ug | 8375.4 | ipatherapeutics |
PODI-0082 | mouse anti-human CD63 | 100ug | 8375.4 | ipatherapeutics |
PODI-0083 | mouse anti-human CD31 | 100ug | 8375.4 | ipatherapeutics |
PODI-0084 | mouse anti-human CD41 | 100ug | 8375.4 | ipatherapeutics |
PODI-0085 | mouse anti-human CD61 | 100ug | 8375.4 | ipatherapeutics |
PODI-0086 | mouse anti-human CD42B | 100ug | 8375.4 | ipatherapeutics |
PODI-0087 | mouse anti-human vWF | 100ug | 8375.4 | ipatherapeutics |
PODI-0088 | mouse anti-Thrombospondin | 100ug | 8375.4 | ipatherapeutics |
PODI-0089 | mouse anti-Annexin-5 | 100ug | 8375.4 | ipatherapeutics |
PODI-0090 | mouse anti-human Protein S | 100ug | 8375.4 | ipatherapeutics |
PODI-0091 | mouse anti-CD40 (8B9) | 100ug | 8375.4 | ipatherapeutics |
PODI-0092 | mouse anti-CD40 (16B4E4) | 100ug | 8375.4 | ipatherapeutics |
PODI-0093 | mouse anti-NY-ESO | 100ug | 8375.4 | ipatherapeutics |
地址：上海浦東川沙鎮(zhèn)川沙路6619號(hào)上海起發(fā)實(shí)驗(yàn)試劑有限公司
郵箱：xs1@78bio.com
傳真：021-50724961
電話
微信
當(dāng)前位置：